179 related articles for article (PubMed ID: 25443341)
21. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
Lemoine M; Thursz M
Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
[TBL] [Abstract][Full Text] [Related]
23. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
Belda O; Targett-Adams P
Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
[TBL] [Abstract][Full Text] [Related]
25. Drug Pricing Evolution in Hepatitis C.
Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C eradication: A long way to go.
Waheed Y
World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
[TBL] [Abstract][Full Text] [Related]
27. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals.
Su PS; Su CW; Wu SH; Wei TH; Chu CJ; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2021 May; 84(5):465-471. PubMed ID: 33871393
[TBL] [Abstract][Full Text] [Related]
28. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
29. Strategies for access to affordable hepatitis C testing and treatment in Asia.
Khwairakpam G; Burry J
Curr Opin HIV AIDS; 2019 Jan; 14(1):1-6. PubMed ID: 30480583
[TBL] [Abstract][Full Text] [Related]
30. What is the future of ribavirin therapy for hepatitis C?
Koh C; Liang TJ
Antiviral Res; 2014 Apr; 104():34-9. PubMed ID: 24468277
[TBL] [Abstract][Full Text] [Related]
31. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
33. Treatment of non-genotype 1 hepatitis C virus patients.
Mangia A; Mottola L
Curr Gastroenterol Rep; 2012 Feb; 14(1):87-93. PubMed ID: 22113745
[TBL] [Abstract][Full Text] [Related]
34. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
Oru E; Trickey A; Shirali R; Kanters S; Easterbrook P
Lancet Glob Health; 2021 Apr; 9(4):e431-e445. PubMed ID: 33639097
[TBL] [Abstract][Full Text] [Related]
35. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
36. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
37. Direct-acting antivirals: the endgame for hepatitis C?
D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
[TBL] [Abstract][Full Text] [Related]
38. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
Easterbrook P; Sands A; Harmanci H
Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
[TBL] [Abstract][Full Text] [Related]
39. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C Virus: Viral Quasispecies and Genotypes.
Tsukiyama-Kohara K; Kohara M
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
